<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28652279</article-id><article-id pub-id-type="pmc">5634769</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0235</article-id><article-id pub-id-type="publisher-id">ONCO12194</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>6</subject><subject>26</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>Pregabalin for the Prevention of Oxaliplatin&#x02010;Induced Painful Neuropathy: A Randomized, Double&#x02010;Blind Trial</article-title></title-group><contrib-group><contrib id="onco12194-cr-0001" contrib-type="author" corresp="yes"><name><surname>de Andrade</surname><given-names>Daniel Ciampi</given-names></name><address><email>ciampi@usp.br</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12194-cr-0002" contrib-type="author"><name><surname>Jacobsen Teixeira</surname><given-names>Manoel</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12194-cr-0003" contrib-type="author"><name><surname>Galhardoni</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0011"><sup>k</sup></xref></contrib><contrib id="onco12194-cr-0004" contrib-type="author"><name><surname>Ferreira</surname><given-names>Karine S.L.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-0005" contrib-type="author"><name><surname>Braz Mileno</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12194-cr-0006" contrib-type="author"><name><surname>Scisci</surname><given-names>Nathalia</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-0007" contrib-type="author"><name><surname>Zandonai</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-0008" contrib-type="author"><name><surname>Teixeira</surname><given-names>William G.J.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-0009" contrib-type="author"><name><surname>Saragiotto</surname><given-names>Daniel F.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00010" contrib-type="author"><name><surname>Silva</surname><given-names>Valqu&#x000ed;ria</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-00011" contrib-type="author"><name><surname>Raicher</surname><given-names>Irina</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12194-cr-00012" contrib-type="author"><name><surname>Cury</surname><given-names>Rubens Gisbert</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00013" contrib-type="author"><name><surname>Macarenco</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00014" contrib-type="author"><name><surname>Otto Heise</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="onco12194-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12194-cr-00015" contrib-type="author"><name><surname>Wilson Iervolino Brotto</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="onco12194-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12194-cr-00016" contrib-type="author"><name><surname>Andrade de Mello</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="onco12194-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12194-cr-00017" contrib-type="author"><name><surname>Zini Megale</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="onco12194-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12194-cr-00018" contrib-type="author"><name><surname>Henrique Curti Dourado</surname><given-names>Luiz</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-00019" contrib-type="author"><name><surname>Mendes Bahia</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12194-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12194-cr-00020" contrib-type="author"><name><surname>Lilian Rodrigues</surname><given-names>Antonia</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-00021" contrib-type="author"><name><surname>Parravano</surname><given-names>Daniella</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-00022" contrib-type="author"><name><surname>Tizue Fukushima</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00023" contrib-type="author"><name><surname>Lefaucheur</surname><given-names>Jean&#x02010;Pascal</given-names></name><xref ref-type="aff" rid="onco12194-aff-0006"><sup>f</sup></xref></contrib><contrib id="onco12194-cr-00024" contrib-type="author"><name><surname>Bouhassira</surname><given-names>Didier</given-names></name><xref ref-type="aff" rid="onco12194-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12194-cr-00025" contrib-type="author"><name><surname>Sobroza</surname><given-names>Evandro</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00026" contrib-type="author"><name><surname>Riechelmann</surname><given-names>Rachel P.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00027" contrib-type="author"><name><surname>Hoff</surname><given-names>Paulo M.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-00028" contrib-type="author"><collab collab-type="authors">PreOx Workgroup</collab></contrib><contrib id="onco12194-cr-0029" contrib-type="author"><name><surname>Val&#x000e9;rio da Silva</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="onco12194-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12194-cr-0030" contrib-type="author"><name><surname>Chile</surname><given-names>Thais</given-names></name><xref ref-type="aff" rid="onco12194-aff-0009"><sup>i</sup></xref></contrib><contrib id="onco12194-cr-0031" contrib-type="author"><name><surname>Dale</surname><given-names>Camila S.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0008"><sup>h</sup></xref></contrib><contrib id="onco12194-cr-0032" contrib-type="author"><name><surname>Nebuloni</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-0033" contrib-type="author"><name><surname>Senna</surname><given-names>Luiz</given-names></name><xref ref-type="aff" rid="onco12194-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12194-cr-0034" contrib-type="author"><name><surname>Brentani</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="onco12194-aff-0009"><sup>i</sup></xref></contrib><contrib id="onco12194-cr-0035" contrib-type="author"><name><surname>Pagano</surname><given-names>Rosana L.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0010"><sup>j</sup></xref></contrib><contrib id="onco12194-cr-0036" contrib-type="author"><name><surname>de Souza</surname><given-names>&#x000c2;ngela M.</given-names></name><xref ref-type="aff" rid="onco12194-aff-0002"><sup>b</sup></xref></contrib><aff id="onco12194-aff-0001"><label><sup>a</sup></label><institution>Centro de Dor, Departamento de Neurologia, Universidade de Sao Paulo</institution>, <city>Sao Paulo</city>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0002"><label><sup>b</sup></label><institution>Centro de Dor, Instituto do Cancer do Estado de S&#x000e3;o Paulo</institution>, <city>S&#x000e3;o Paulo</city>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0003"><label><sup>c</sup></label><institution>Divis&#x000e3;o de Neurocirurgia, Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de Sao Paulo</institution>, <city>Sao Paulo</city>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0004"><label><sup>d</sup></label>
<named-content content-type="organisation-division">Departamento de Neurologia</named-content>, <institution>Universidade de Sao Paulo</institution>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0005"><label><sup>e</sup></label><institution>Instituto do Cancer do Estado de S&#x000e3;o Paulo, Faculdade de Medicina da Universidade de Sao Paulo</institution>, <city>Sao Paulo</city>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0006"><label><sup>f</sup></label><institution>Clinical Neurophysiology Unit, Department of Physiology, Henri Mondor University Hospital, AP&#x02010;HP</institution>, <city>Cr&#x000e9;teil</city>, <country country="BR">France</country>
</aff><aff id="onco12194-aff-0007"><label><sup>g</sup></label><institution>INSERM U-987, Centre d'Evaluation et de Traitement de la Douleur, H&#x000f4;pital Ambroise Par&#x000e9;</institution>, <city>Boulogne</city>, <country country="BR">France</country>
</aff><aff id="onco12194-aff-0008"><label><sup>h</sup></label>
<named-content content-type="organisation-division">Departamento de Anatomia</named-content>, <institution>Instituto de Ci&#x000ea;ncias Biomedicas, Universidade de Sao Paulo</institution>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0009"><label><sup>i</sup></label><institution>LIM 23, Instituto de Psiquiatria, Universidade de Sao Paulo</institution>, <country country="BR">Brazil</country>
</aff><aff id="onco12194-aff-0010"><label><sup>j</sup></label><institution>Laboratory of Neuromodulation and Experimental Pain, Hospital S&#x000ed;rio Liban&#x000ea;s</institution>, <country country="FR">Brazil</country>
</aff><aff id="onco12194-aff-0011"><label><sup>k</sup></label><institution>Medical School of University of City of S&#x000e3;o Paulo (UNICID)</institution>, <city>S&#x000e3;o Paulo</city>, <country country="FR">Brazil</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Daniel Ciampi de Andrade, M.D., Ph.D., Instituto de Cancer do Estado de S&#x000e3;o Paulo, University of S&#x000e3;o Paulo, rua dr eneas de carvalho aguiar, Sao Paulo 05410002, Brazil. Telephone: +55&#x02010;11&#x02010;97280&#x02010;0027; e&#x02010;mail: <email>ciampi@usp.br</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>6</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>10</issue><issue-id pub-id-type="doi">10.1002/onco.v22.10</issue-id><fpage>1154</fpage><lpage>e105</lpage><history><date date-type="received"><day>27</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9;AlphaMedPress; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12194.pdf"/><abstract><title>Abstract</title><sec id="onco12194-sec-0281"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12194-list-0002"><list-item id="onco12194-li-0001"><p>Pregabalin is a medication that can decrease neuronal hyperexcitability, relieve neuropathic pain, and reach stable plasma levels after a titration period of only a few days.</p></list-item><list-item id="onco12194-li-0002"><p>Its use during oxaliplatin infusions was not able to decrease the incidence of chronic, oxalipaltin&#x02010;related neuropathic pain, compared with placebo.</p></list-item></list></p></sec><sec id="onco12194-sec-0001"><title>Background.</title><p>Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin&#x02010;induced peripheral neuropathy (OXAIPN). Acute and chronic OXA&#x02010;related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: central sensitization (CS) of nociceptive neuronal networks, leading to increased sensitivity (hyperlgesia, allodynia) in the somatosensory system, the common ground of chronic neuropathic pain. Because CS is related to increased risk of painful OXAIPN, we hypothesized that preemptive use of the anti&#x02010;hyperalgesic drug pregabaline (known to decrease CS) during OXA infusions would decrease the incidence of chronic OXAIPN.</p></sec><sec id="onco12194-sec-0002"><title>Methods.</title><p>Pain&#x02010;free, chemotherapy&#x02010;na&#x000ef;ve CRC patients receiving at least one cycle of modified&#x02010;FLOX [5&#x02010;FU(500 mg/m<sup>2</sup>)+leucovorin(20 mg/m<sup>2</sup>)/week for] 6 weeks+oxaliplatin(85 mg/m<sup>2</sup>) at weeks 1&#x02010;3&#x02010;5 every 8 weeks] were randomized (1:1) into the study. Patients received either pregabalin or placebo for 3 days before and 3 days after each OXA infusion and were followed for up to 6 months. Clinical assessments were performed at baseline, at the end of chemotherapy, and after the follow&#x02010;up period. The main outcome was average pain at the last visit assessed by the visual analogic scale (0&#x02013;10) item of the Brief Pain Inventory (BPI). Secondary endpoints were presence of neuropathic pain according to the Douleur Neuropathique&#x02010;4 (DN&#x02010;4), pain dimensions (short&#x02010; form McGill Pain Questionnaire [MPQ]), Neuropathic Pain Symptom Inventory (NPSI), and changes in nerve conduction studies (NCS) and side effect profile.</p></sec><sec id="onco12194-sec-0003"><title>Results.</title><p>One hundred ninety&#x02010;nine patients (57.0&#x02009;&#x000b1;&#x02009;10.7 years old, 98 female, 101 male) were randomized. Data from 56 patients were not included in the analyses (as they did not receive at least one full cycle of modified FLOX). Data from 78 patients in the pregabalin group and 65 patients in the placebo group were retained for analyses. At the last visit, pain intensity in the pregabalin group was 1.03 (95% confidence interval [CI]&#x02009;=&#x02009;0.79&#x02013;1.26), and 0.85 (95% CI&#x02009;=&#x02009;0.64&#x02013;1.06) in the placebo group, which did not reach significance. Scores from the BPI, MPQ, DN&#x02010;4, NPSI, and NCS and side&#x02010;effect profiles and incidence of death did not differ between groups. Quality of life (QoL) score did not differ between groups (placebo&#x02009;=&#x02009;76.9&#x02009;&#x000b1;&#x02009;23.1, pregabalin group 79.4&#x02009;&#x000b1;&#x02009;20.6). Mood scores were not significantly different between groups (placebo 9.7 [8.1&#x02013;11.2]; pregabalin 6.8 [5.6&#x02013;8.0]).</p></sec><sec id="onco12194-sec-0004"><title>Conclusion.</title><p>The preemptive use of pregabalin during OXA infusions was safe, but did not decrease the incidence of chronic pain related to OXAIPN.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh"><bold>&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</bold></p><p xml:lang="zh">&#x02022; &#x0666e;&#x0745e;&#x05df4;&#x06797;&#x053ef;&#x051cf;&#x08f7b;&#x0795e;&#x07ecf;&#x05143;&#x08fc7;&#x05ea6;&#x05174;&#x0594b;&#x0548c;&#x07f13;&#x089e3;&#x0795e;&#x07ecf;&#x06027;&#x075bc;&#x075db;, &#x04ec5;&#x06ef4;&#x05b9a;&#x051e0;&#x05929;&#x0540e;&#x05373;&#x053ef;&#x08fbe;&#x05230;&#x07a33;&#x05b9a;&#x07684;&#x08840;&#x06d46;&#x06c34;&#x05e73;&#x03002;</p><p xml:lang="zh">&#x02022; &#x04e0e;&#x05b89;&#x06170;&#x05242;&#x076f8;&#x06bd4;, &#x05728;&#x05965;&#x06c99;&#x05229;&#x094c2;&#x08f93;&#x06ce8;&#x07ed9;&#x0836f;&#x0671f;&#x095f4;&#x04f7f;&#x07528;&#x0666e;&#x0745e;&#x05df4;&#x06797;&#x065e0;&#x06cd5;&#x0964d;&#x04f4e;&#x04e0e;&#x05965;&#x06c99;&#x05229;&#x094c2;&#x076f8;&#x05173;&#x07684;&#x06162;&#x06027;&#x0795e;&#x07ecf;&#x06027;&#x075bc;&#x075db;&#x07684;&#x053d1;&#x0751f;&#x07387;&#x03002;</p><p xml:lang="zh"><bold>&#x06458;&#x08981;</bold></p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic>.</bold>&#x09ed1;&#x08272;&#x07d20;&#x07624;&#x0884d;&#x0751f;&#x07684;&#x070ed;&#x04f11;&#x0514b;&#x086cb;&#x0767d;&#x0ff08;HSP&#x0ff09;&#x0548c;HSP&#x02010;&#x080bd;&#x0590d;&#x05408;&#x07269;&#x053ef;&#x04ee5;&#x05f15;&#x053d1;&#x04fdd;&#x062a4;&#x06027;&#x06297;&#x080bf;&#x07624;&#x053cd;&#x05e94;&#x03002;&#x07c92;&#x07ec6;&#x080de;&#x02010;&#x05de8;&#x0566c;&#x07ec6;&#x080de;&#x096c6;&#x0843d;&#x0523a;&#x06fc0;&#x056e0;&#x05b50;&#x0ff08;GM&#x02010;CSF&#x0ff09;&#x08d8b;&#x05316;&#x056e0;&#x05b50;&#x04e5f;&#x053ef;&#x04fc3;&#x08fdb;&#x04e13;&#x0804c;&#x06297;&#x0539f;&#x05448;&#x09012;&#x07ec6;&#x080de;&#x0ff08;APC&#x0ff09;&#x07684;&#x06444;&#x053d6;&#x0548c;&#x052a0;&#x05de5;&#x05904;&#x07406;&#x03002;&#x05728;&#x06b64;&#x057fa;&#x07840;&#x04e0a;, &#x06211;&#x04eec;&#x08bbe;&#x08ba1;&#x04e86;&#x04e00;&#x09879;&#x07ecf;&#x076ae;&#x070ed;&#x06d88;&#x0878d;&#x0521d;&#x06b65;&#x07814;&#x07a76;, &#x0636e;&#x06b64;&#x08bf1;&#x05bfc;&#x070ed;&#x04f11;&#x0514b;&#x086cb;&#x0767d;&#x075ab;&#x082d7;&#x04e0e;GM&#x02010;CSF, &#x04ee5;&#x0786e;&#x05b9a;&#x08fd9;&#x079cd;&#x08054;&#x05408;&#x07684;&#x05b89;&#x05168;&#x06027;&#x0548c;&#x0521d;&#x06b65;&#x06297;&#x080bf;&#x07624;&#x06548;&#x0679c;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x06750;&#x06599;&#x0548c;&#x065b9;&#x06cd5;</italic>.</bold>&#x0672c;&#x07814;&#x07a76;&#x065e8;&#x05728;&#x08bc4;&#x04f30;&#x07ecf;&#x076ae;&#x06d88;&#x0878d;&#x08054;&#x05408;GM&#x02010;CSF&#x07528;&#x04e8e;&#x04e0d;&#x053ef;&#x05207;&#x09664;&#x07684;&#x08f6c;&#x079fb;&#x06027;&#x09ed1;&#x08272;&#x07d20;&#x07624;&#x0ff08;&#x05305;&#x062ec;&#x08461;&#x08404;&#x0819c;&#x0548c;&#x07c98;&#x0819c;&#x0578b;&#x0ff09;&#x07684;&#x0603b;&#x04f53;&#x05b89;&#x05168;&#x06027;&#x03002;&#x06240;&#x06709;&#x060a3;&#x08005;&#x09996;&#x05148;&#x063a5;&#x053d7;&#x070ed;&#x04f11;&#x0514b;&#x06cbb;&#x07597;&#x0ff08;42&#x000b0;C, 30&#x05206;&#x0949f;&#x0ff09;, &#x07136;&#x0540e;&#x063a5;&#x053d7;&#x04ee5;&#x04e0b;&#x04e09;&#x079cd;&#x06cbb;&#x07597;&#x065b9;&#x06cd5;&#x04e4b;&#x04e00;&#x0ff1a;&#x0ff08;a&#x0ff09;&#x075c5;&#x07076;&#x05185;GM&#x02010;CSF&#x0ff08;500 mcg&#x06807;&#x051c6;&#x05242;&#x091cf;&#x0ff09;&#x0ff1b;&#x0ff08;b&#x0ff09;&#x05c04;&#x09891;&#x06d88;&#x0878d;&#x0ff08;RFA&#x0ff09;+GM&#x02010;CSF&#x0ff1b;&#x06216;&#x0ff08;c&#x0ff09;&#x051b7;&#x051bb;&#x06d88;&#x0878d;&#x08054;&#x05408;GM&#x02010;CSF&#x03002;&#x07814;&#x07a76;&#x07684;&#x04e3b;&#x08981;&#x07ec8;&#x070b9;&#x0662f;&#x08bf1;&#x05bfc;&#x05185;&#x06e90;&#x06027;HSP70&#x0548c;&#x09ed1;&#x08272;&#x07d20;&#x07624;&#x07279;&#x05f02;&#x06027;&#x07ec6;&#x080de;&#x06bd2;&#x06027;T&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x0ff08;CTL&#x0ff09;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic>.</bold>&#x05165;&#x07ec4;&#x04e86;&#x04e5d;&#x0540d;&#x060a3;&#x08005;&#x0ff08;&#x06bcf;&#x04e2a;&#x07814;&#x07a76;&#x07ec4;&#x04e09;&#x0540d;&#x0ff09;&#x03002;&#x06309;&#x07167;&#x065b9;&#x06848;&#x089c4;&#x05b9a;, &#x0672a;&#x089c2;&#x05bdf;&#x05230;&#x05242;&#x091cf;&#x09650;&#x05236;&#x06027;&#x06bd2;&#x06027;&#x03002;&#x06240;&#x06709;&#x060a3;&#x08005;&#x05747;&#x053d1;&#x0751f;&#x04e86;&#x075be;&#x075c5;&#x08fdb;&#x05c55;, &#x05e76;&#x07ee7;&#x07eed;&#x063a5;&#x053d7;&#x066ff;&#x04ee3;&#x06cbb;&#x07597;&#x03002;&#x04e2d;&#x04f4d;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x04e3a;8.2&#x04e2a;&#x06708;[95&#x0ff05;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff08;CI&#x0ff09;2&#x02010;17.2]&#x03002;&#x08be5;&#x07814;&#x07a76;&#x07684;&#x0628a;&#x063e1;&#x05ea6;&#x04e0d;&#x08db3;&#x04ee5;&#x068c0;&#x051fa;&#x06cbb;&#x07597;&#x07ec4;&#x095f4;&#x04e34;&#x05e8a;&#x07ed3;&#x05c40;&#x07684;&#x05dee;&#x05f02;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic>.</bold>&#x07ecf;&#x076ae;&#x070ed;&#x06d88;&#x0878d;&#x08054;&#x05408;GM&#x02010;CSF&#x05177;&#x06709;&#x0826f;&#x0597d;&#x07684;&#x08010;&#x053d7;&#x06027;&#x04e14;&#x05728;&#x06280;&#x0672f;&#x04e0a;&#x053ef;&#x0884c;, &#x05176;&#x04e0d;&#x0826f;&#x04e8b;&#x04ef6;&#x07279;&#x05f81;&#x088ab;&#x08bc1;&#x05b9e;&#x053ef;&#x063a5;&#x053d7;&#x05e76;&#x04e14;&#x04e0e;&#x05e38;&#x089c4;RFA&#x0548c;&#x051b7;&#x051bb;&#x06d88;&#x0878d;&#x076f8;&#x04f3c;&#x03002;HSP70&#x05728;&#x06cbb;&#x07597;&#x0540e;&#x088ab;&#x08bf1;&#x05bfc;, HSP70&#x05347;&#x09ad8;&#x07a0b;&#x05ea6;&#x04e0e;&#x04e34;&#x05e8a;&#x07ed3;&#x05c40;&#x06216;&#x08bf1;&#x05bfc;&#x07684;CTL&#x05e94;&#x07b54;&#x065e0;&#x05173;&#x03002;&#x0867d;&#x07136;&#x05728;&#x0672a;&#x06765;&#x07684;&#x07814;&#x07a76;&#x04e2d;&#x053ef;&#x04ee5;&#x08003;&#x08651;&#x08054;&#x05408;&#x04f7f;&#x07528;&#x07ecf;&#x076ae;&#x070ed;&#x06d88;&#x0878d;&#x04e0e;GM&#x02010;CSF&#x0ff08;&#x05305;&#x062ec;&#x068c0;&#x067e5;&#x070b9;&#x06291;&#x05236;&#x05242;&#x0ff09;, &#x04f46;GM&#x02010;CSF&#x07684;&#x04f7f;&#x07528;&#x04ecd;&#x07136;&#x0662f;&#x05b9e;&#x09a8c;&#x06027;&#x07684;, &#x05e76;&#x04e14;&#x0662f;&#x05728;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x08303;&#x056f4;&#x05185;&#x04f7f;&#x07528;&#x03002;</p></trans-abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="onco12194-sec-0005"><title>Discussion</title><p>The intensity of acute OXA&#x02010;induced neuropathic phenomena may significantly increase the odds of developing chronic long&#x02010;term neuropathy. The association between intense acute sensory symptoms and greater risk of developing chronic pain has been described in other settings and is probably related to the development of central neuronal plastic changes such as central sensitization after acute injury. Thus, it has been hypothesized that the modulation of neuronal firing related to acute pain by the use of pregabalin would decrease the likelihood of the development of neuropathic pain.</p><fig fig-type="Figure" xml:lang="en" id="onco12194-fig-0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Consolidated Standards of Reporting Trials flowchart of screened and included patients.</p></caption><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12194-fig-0001"><alt-text>image</alt-text></graphic></fig><p>Based on this rationale, we tested the hypothesis that the preemptive use of pregabalin a few days before and after OXA would have a preventive effect on chronic OXAIPN and its most troublesome symptom: neuropathic pain. However, we found no effects of pregabalin in this scenario. It failed to impact both the acute and chronic pains seen after OXA. Pain&#x02010;related effects, interference, and QoL were not influenced by the active treatment.</p></sec><sec id="onco12194-sec-1101"><title>Trial Information</title><p><def-list id="onco12194-lp-0001"><def-item><term id="onco12194-li-0003"><bold>Disease</bold></term><def id="onco12194-li-0004"><p>CRC</p></def></def-item><def-item><term id="onco12194-li-0005"><bold>Stage of Disease/Treatment</bold></term><def id="onco12194-li-0006"><p>Prevention</p></def></def-item><def-item><term id="onco12194-li-0007"><bold>Prior Therapy</bold></term><def id="onco12194-li-0008"><p>None</p></def></def-item><def-item><term id="onco12194-li-0009"><bold>Type of study &#x02010; 1</bold></term><def id="onco12194-li-0010"><p>Phase III</p></def></def-item><def-item><term id="onco12194-li-0011"><bold>Type of study &#x02010; 2</bold></term><def id="onco12194-li-0012"><p>Randomized</p></def></def-item><def-item><term id="onco12194-li-0013"><bold>Primary Endpoint</bold></term><def id="onco12194-li-0014"><p>Pain intensity</p></def></def-item><def-item><term id="onco12194-li-0015"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0016"><p>Safety</p></def></def-item><def-item><term id="onco12194-li-0017"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0018"><p>QoL</p></def></def-item><def-item><term id="onco12194-li-0019"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0020"><p>Cummulative mFLOX dose</p></def></def-item><def-item><term id="onco12194-li-0021"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0022"><p>NPSI score</p></def></def-item><def-item><term id="onco12194-li-0023"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0024"><p>Presence of neuropathic pain</p></def></def-item><def-item><term id="onco12194-li-0025"><bold>Secondary Endpoint</bold></term><def id="onco12194-li-0026"><p>CTC&#x02010;neuropathy</p></def></def-item><def-item><term id="onco12194-li-0027"><bold>Additional Details of Endpoints or Study Design</bold></term><def id="onco12194-li-1027"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0028">Pain characterization: Pain intensity and interference with daily activities were assessed by the short-form of the Brief Pain Inventory (BPI), which evaluates current pain intensity as well as the worst, least, and average (study's main outcome) pain intensity (11&#x02010;point scale) in the previous 24 hours. The BPI also assesses pain interference with daily activities (general activities, mood, walking, work, relationships with others, sleep, and enjoyment of life) in an 11&#x02010;point scale from 0 (no pain/no interference) to 10 (as severe as possible) [<xref rid="onco12194-bib-0028" ref-type="ref">28</xref>]. The McGill Pain Questionnaire (MPQ)-short form assesses different dimensions of pain (sensory, affective, and evaluative) [<xref rid="onco12194-bib-0029" ref-type="ref">29</xref>], [<xref rid="onco12194-bib-0030" ref-type="ref">30</xref>]. Assessments took place 1 week after each OXA infusion at planned visits and during the follow-up period by research nurses not implicated in OXA administration. The presence of neuropathic pain characteristics was assessed by the Douleur Neuropathique-4 (0&#x02013;10, positive &#x02265;4) [<xref rid="onco12194-bib-0031" ref-type="ref">31</xref>]. Neuropathic Pain Symptom Inventory (0&#x02013;100) was used for neuropathic pain profiling [<xref rid="onco12194-bib-0032" ref-type="ref">32</xref>], [<xref rid="onco12194-bib-0033" ref-type="ref">33</xref>].</term><def id="onco12194-li-1397"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0029">Oxaliplatin-Related Neuropathy: The presence of neuropathy was assessed by the reduced version of the total neuropathy score (rTNS) [<xref rid="onco12194-bib-0034" ref-type="ref">34</xref>] at baseline and at the last visit by blinded neurophysiologists with no other role in the study. The severity of oxaliplatin-induced neuropathy was assessed by the NCI-CTCv3 [<xref rid="onco12194-bib-0034" ref-type="ref">34</xref>], [<xref rid="onco12194-bib-0035" ref-type="ref">35</xref>], [<xref rid="onco12194-bib-0036" ref-type="ref">36</xref>].</term><def id="onco12194-li-1077"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0030">Concomitant Analgesic Medication Use: The number of psychotropic analgesics used during the trial was quantified in each visit by the BPI. The use of alpha-2-delta (pregabalin and gabapentin) ligands outside the protocol was not allowed during the study.</term><def id="onco12194-li-1897"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0031">Quality of Life and Patient Report Outcomes: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire&#x02010;Core (EORTC&#x02010;QLQ&#x02010;C30v3)&#x02010;items 29/30 were used to evaluate general health and quality of life (QoL). Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale (HADS) [<xref rid="onco12194-bib-0037" ref-type="ref">37</xref>], which provides anxiety (0&#x02013;21) and depression (0&#x02013;21) scores.</term><def id="onco12194-li-1197"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0032">Safety: Safety was assessed by the presence and severity of adverse effects (AEs), discontinuation and death. CTCAE term (AE description) and grades were recorded according to the NCI&#x02010;CTCAE&#x02010;v3.0 [<xref rid="onco12194-bib-0035" ref-type="ref">35</xref>].</term><def id="onco12194-li-1297"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0033">Statistical Methods: Descriptive data analysis presented categorical variables as observed counts, and continuous variables as mean/median with the corresponding standard errors/range. The exploratory analysis evaluated distributions, frequencies, and percentages for each of the numeric and categorical variables. Categorical variables were evaluated for near-zero variation [<xref rid="onco12194-bib-0038" ref-type="ref">38</xref>]. Extensive graphical displays were used for both univariate analysis and bivariate associations, accompanied by tests such as the maximal information coefficient [<xref rid="onco12194-bib-0039" ref-type="ref">39</xref>] and non-negative matrix factorization algorithms [<xref rid="onco12194-bib-0018" ref-type="ref">18</xref>] for numeric variables. Missing data were explored using a combination of graphical displays involving univariate, bivariate, and multivariate methods. Imputation was performed using a k-nearest neighbor's algorithm (<italic>n</italic>&#x02009;=&#x02009;5) [<xref rid="onco12194-bib-0040" ref-type="ref">40</xref>]. Balance at baseline was evaluated through one-way analysis of variance and chi-square tests. These tests were conducted with both the originally randomized sample as well as with those meeting the criteria for inclusion in the final analysis, based on time in the study and minimum time providing outcomes data. After balance evaluation, the modeling strategy employed a series of generalized estimating equation models to evaluate the association between all previously reported outcomes and the intervention versus placebo, accounting for all intermediate follow-up measurements. Of importance, confounding adjustment was applied to our analyses to account for bias resulting from imbalances generated through dropout rates and exclusion criteria.</term><def id="onco12194-li-1327"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0034">Results were reported as predicted means for numeric outcomes (significance was present when 95% CI values from each variable did not intersect between groups) and odds ratios for Boolean (yes/no) outcomes with 95% CI. Per protocol, our main results concerned participants who provided outcome data beyond visit eight (i.e., patients who receive at least 2 months of chemotherapy and were followed for at least 3 months, thus staying in the protocol for at least 5 months). However, the analyses also followed an intention&#x02010;to&#x02010;treat protocol by performing a sensitivity analysis where all subjects were included regardless of their follow&#x02010;up time or therapy. A single post&#x02010;hoc analysis was reported as per our protocol, stratifying outcomes by the presence of metastasis at baseline. All analyses were performed using the R&#x02010;statistical language. A sample of 154 patients randomly assigned to the treatment or placebo group (77 for each arm) was required for 90% power and type&#x02010;I error = 0.05. Taking into account the prevalence of acute OXAIPN and 30% losses due to deaths/dropouts during the follow&#x02010;up, we estimated 100 participants per group would be appropriate.</term><def id="onco12194-li-1097"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0035"><bold>Investigator's Analysis</bold></term><def id="onco12194-li-0036"><p>Level of activity did not meet planned endpoint</p></def></def-item></def-list>
</p></sec><sec id="onco12194-sec-1281"><title>Drug Information for Phase III Pregabalin</title><p><def-list id="onco12194-lp-0002"><def-item><term id="onco12194-li-0037"><bold>Drug 1</bold></term><def id="onco12194-li-0038"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0039"><bold>Generic/Working name</bold></term><def id="onco12194-li-0040"><p>Pregabalin</p></def></def-item><def-item><term id="onco12194-li-0041"><bold>Trade name</bold></term><def id="onco12194-li-0042"><p>Lyrica</p></def></def-item><def-item><term id="onco12194-li-0043"><bold>Company name</bold></term><def id="onco12194-li-0044"><p>Pfizer</p></def></def-item><def-item><term id="onco12194-li-0045"><bold>Drug type</bold></term><def id="onco12194-li-0046"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0047"><bold>Drug class</bold></term><def id="onco12194-li-0048"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0049"><bold>Dose</bold></term><def id="onco12194-li-0050"><p>150&#x02013;600 mg p.o. q.d. milligrams (mg) per flat dose</p></def></def-item><def-item><term id="onco12194-li-0051"><bold>Route</bold></term><def id="onco12194-li-0052"><p>Oral (p.o.)</p></def></def-item><def-item><term id="onco12194-li-0053"><bold>Schedule of administration</bold></term><def id="onco12194-li-1127"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0054">This was a double-blind, placebo-controlled randomized trial. Patients referred to our institution's outpatient clinic were screened for participation and were randomized in blocks of twenty to receive either placebo or pregabalin (1:1). Oral medication (pregabalin or placebo) was taken in an outpatient setting intermittently in flexible daily doses of 150&#x02013;600 mg in a time period extending from 3 days before to 3 days after each OXA infusion (i.e., weeks 1&#x02010;3&#x02010;5 in each of the three cycles). During the 4 days preceding the very first infusion of OXA in the study, the dose of pregabalin or placebo was progressively titrated from 75 mg b.i.d. up to 300 mg b.i.d. Titration was monitored by programmed phone calls from study nurses blinded to the treatment arm, who coached patients to take medications and adjust the daily dose of medication according to each individual's tolerance and side effects profile, according to a standardized protocol. Thus, patients had medication titrated up to their highest tolerable dosage before the first Oxa infusion (150 mg increase/day), and from this point onward, this individualized dosage was used in a fixed-dose regimen (starting at the top dose from beginning) 3 days before and 3 days after each of the following Oxa infusions throughout the study. Patients were considered noncompliant to the protocol when presenting more than three absences in protocol visits or in case of failure to take more than 50% of the expected study medication dose before more than two treatment infusions of OXA. Compliance was assessed by counting empty blisters. Allocation concealment was assured by the use of opaque envelopes labeled with a code designating the study protocol number of each participant and the study group.</term><def id="onco12194-li-1087"><p>&#x000a0;</p></def></def-item></def-list>
</p></sec><sec id="onco12194-sec-1201"><title>Drug Information for Phase III Placebo</title><p><def-list id="onco12194-lp-0003"><def-item><term id="onco12194-li-0055"><bold>Drug 1</bold></term><def id="onco12194-li-0056"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0057"><bold>Generic/Working name</bold></term><def id="onco12194-li-0058"><p>Placebo</p></def></def-item><def-item><term id="onco12194-li-0059"><bold>Trade name</bold></term><def id="onco12194-li-0060"><p>Placebo</p></def></def-item><def-item><term id="onco12194-li-0061"><bold>Drug type</bold></term><def id="onco12194-li-0062"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0063"><bold>Drug class</bold></term><def id="onco12194-li-0064"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0065"><bold>Dose</bold></term><def id="onco12194-li-0066"><p>150&#x02013;600 milligrams (mg) per flat dose</p></def></def-item><def-item><term id="onco12194-li-0067"><bold>Route</bold></term><def id="onco12194-li-0068"><p>Oral (p.o.)</p></def></def-item><def-item><term id="onco12194-li-0069"><bold>Schedule of administration</bold></term><def id="onco12194-li-1227"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0070">(a) Chemo regimen: patients were scheduled to receive modified&#x02010;FLOX (5&#x02010;FU bolus 500 mg/m<sup>2</sup>&#x02009;+&#x02009;bolus of leucovorin 200 mg/m<sup>2</sup>/week for 6 weeks&#x02009;+&#x02009;OXA 85 mg/m<sup>2</sup> in 2 hour&#x02010;infusions at weeks 1&#x02013;3&#x02010;5 every 8 weeks)</term><def id="onco12194-li-1067"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0071">(b) Intervention: pregabalin: daily, 3 days before and 3 days after OXA infusion; placebo provided in a blister pack identical to that for the pregabalin in the same dose regimen</term><def id="onco12194-li-1068"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0072"><bold>Drug 2</bold></term><def id="onco12194-li-0073"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0074"><bold>Generic/Working name</bold></term><def id="onco12194-li-0075"><p>Placebo</p></def></def-item><def-item><term id="onco12194-li-0076"><bold>Trade name</bold></term><def id="onco12194-li-0077"><p>Placebo</p></def></def-item><def-item><term id="onco12194-li-0078"><bold>Company name</bold></term><def id="onco12194-li-0079"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0080"><bold>Drug type</bold></term><def id="onco12194-li-0081"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0082"><bold>Drug class</bold></term><def id="onco12194-li-0083"><p>Other</p></def></def-item><def-item><term id="onco12194-li-0084"><bold>Dose</bold></term><def id="onco12194-li-0085"><p>150 milligrams (mg) per flat dose</p></def></def-item><def-item><term id="onco12194-li-0086"><bold>Route</bold></term><def id="onco12194-li-0087"><p>Oral (p.o.)</p></def></def-item><def-item><term id="onco12194-li-0088"><bold>Schedule of administration</bold></term><def id="onco12194-li-0089"><p>Similar to pregabalin</p></def></def-item></def-list>
</p></sec><sec id="onco12194-sec-1401"><title>Patient Characteristics for Phase III Pregabalin</title><p><def-list id="onco12194-lp-0004"><def-item><term id="onco12194-li-0090"><bold>Number of patients, male</bold></term><def id="onco12194-li-0091"><p>99</p></def></def-item><def-item><term id="onco12194-li-0092"><bold>Number of patients, female</bold></term><def id="onco12194-li-0093"><p>100</p></def></def-item><def-item><term id="onco12194-li-0094"><bold>Stage</bold></term><def id="onco12194-li-0227"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0095">Eligible patients were chemotherapy&#x02010;na&#x000ef;ve adults with histologically confirmed CRC (stage III/IV) with a Karnofsky Performance Status &#x02265;50, scheduled to receive at least one complete cycle (e.g., three oxapliplatin infusions) of modified&#x02010;FLOX. Exclusion criteria were known central nervous system (CNS) metastasis, uncontrolled concurrent systemic illness, symptoms of peripheral neuropathy (NCI&#x02010;CTCAE&#x02010;v3.0&#x02010;grade &#x02265;1), presence of possible neuropathic pain (Douleur Neuropathique questionnaire &#x02265;4), or positive plasma &#x000df;&#x02010;hCG. The protocol was approved by our institution's Ethics Review Board (007/11) and registered as NCT0145016. All patients gave written informed consent to participate in the study protocol.</term><def id="onco12194-li-0537"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0096">Of 199 subjects undergoing randomization, 143 were included in analyses (Fig. <xref rid="onco12194-fig-0001" ref-type="fig">1</xref>). Additional information on the balance between arms for the entire patient sample is available in supplemental online Table <xref rid="onco12194-tbl-0001" ref-type="table">1</xref>. 90.5% of patients in the pregabalin arm and 91.3% of patients in the placebo arm received at least three complete cycles of modified&#x02010;FLOX (9&#x02010;OXA infusions).</term><def id="onco12194-li-1069"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0097">Fifty&#x02010;six patients were not included in the analyses (pregabalin group: one died before chemo, 20 received less than one chemo cycle and had follow&#x02010;up for less than 3 months, two discontinued chemo; placebo group: two died before chemo started, 25 received less than one chemo cycle and had follow&#x02010;up for less than 3 months, six discontinued chemo).</term><def id="onco12194-li-1070"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0098"><bold>Age</bold></term><def id="onco12194-li-0099"><p>Median (range): 57.13&#x02009;&#x000b1;&#x02009;10.51</p></def></def-item><def-item><term id="onco12194-li-0100"><bold>Number of prior systemic therapies</bold></term><def id="onco12194-li-0101"><p>Median (range): none</p></def></def-item><def-item><term id="onco12194-li-0102"><bold>Cancer types or histologic subtypes</bold></term><def id="onco12194-li-0103"><p>CRC: 199</p></def></def-item></def-list>
</p></sec><sec id="onco12194-sec-1233"><title>Primary Assessment Method for Phase III Pregabalin</title><p><def-list id="onco12194-lp-0005"><def-item><term id="onco12194-li-0104">Assessment</term><def id="onco12194-li-0105"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12194-li-0106">Number of patients screened</term><def id="onco12194-li-0107"><p>402</p></def></def-item><def-item><term id="onco12194-li-0108">Number of patients enrolled</term><def id="onco12194-li-0109"><p>199</p></def></def-item><def-item><term id="onco12194-li-0110">Number of patients evaluable for toxicity</term><def id="onco12194-li-0111"><p>199</p></def></def-item><def-item><term id="onco12194-li-0112">Number of patients evaluated for efficacy</term><def id="onco12194-li-0113"><p>143</p></def></def-item><def-item><term id="onco12194-li-0114">Evaluation method</term><def id="onco12194-li-0115"><p>Clinical (questionnaire and scales)
</p></def></def-item><def-item><term id="onco12194-li-0116">(Median) duration assessments response duration</term><def id="onco12194-li-0117"><p>12 months</p></def></def-item><def-item><term id="onco12194-li-0118">(Median) duration assessments duration of treatment</term><def id="onco12194-li-0119"><p>6 months</p></def></def-item></def-list></p></sec><sec id="onco12194-sec-6235"><title>Adverse Events: Phase III Pregabalin</title><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12194-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12194-note-0003"><p>Abbreviations: NC/NA, no change from baseline/no adverse event.</p></fn><fn id="onco12194-note-0004"><p>Safety was assessed by the presence and severity of AEs, discontinuation, and death. CTCAE term (AE description) and grades were recorded according to the NCI&#x02010;CTCAE&#x02010;v3.0.(17)</p></fn><fn id="onco12194-note-0005"><p>At the last visit, AEs were present in 31% (CTC&#x02010;grade 1&#x02009;=&#x02009;54%) of patients in the pregabalin arm and in 33% of patients (CTC&#x02010;grade 1&#x02009;=&#x02009;50%) in the placebo arm. Twenty&#x02010;six patients died in the pregabalin arm and 25 patients died in the placebo arm during the study, none related to the trial.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12194-sec-1501"><title>Assessment, Analysis, and Discussion</title><p><def-list id="onco12194-lp-0006"><def-item><term id="onco12194-li-0120">Completion</term><def id="onco12194-li-0121"><p>Study completed</p></def></def-item><def-item><term id="onco12194-li-0122">Pharmacokinetics/Pharmacodynamics</term><def id="onco12194-li-0123"><p>Not collected</p></def></def-item><def-item><term id="onco12194-li-0124">Investigator's Assessment</term><def id="onco12194-li-0125"><p>Level of activity did not meet planned endpoint</p></def></def-item></def-list>
</p></sec><sec id="onco12194-sec-0006"><p>The intensity of acute OXA&#x02010;induced neuropathic phenomena may significantly increase the odds of developing chronic long&#x02010;term neuropathy [<xref rid="onco12194-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12194-bib-0002" ref-type="ref">2</xref>]. The association between intense acute sensory symptoms and greater risk of developing chronic pain has been described in other settings [<xref rid="onco12194-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12194-bib-0004" ref-type="ref">4</xref>] and is probably related to the development of central neuronal plastic changes such as central sensitization after acute injury. Central sensitization occurs in central relay centers, such as the spinal cord, and comprises a series of neuronal processes leading to sensory gain in the nervous system [<xref rid="onco12194-bib-0005" ref-type="ref">5</xref>]. In fact, it has been shown that OXA triggers activation of glutamate&#x02010;NMDA receptors in the spinal cord, a major step in central sensitization to painful stimuli [<xref rid="onco12194-bib-0006" ref-type="ref">6</xref>]. Thus, it has been hypothesized that the modulation of the neuronal firing related to acute pain by the use of pregabalin would decrease the likelihood of the development of neuropathic pain. This strategy has been tested in several models of postoperative pain, in which gabapentinoids were administered perioperatively with the aim of decreasing the incidence of long&#x02010;term chronic pain, yielding promising results [<xref rid="onco12194-bib-0007" ref-type="ref">7</xref>]. Also, it has been shown that a single 300&#x02010;mg dose of oral pregabalin was sufficient to reach significant concentrations in the cerebral spinal fluid [<xref rid="onco12194-bib-0008" ref-type="ref">8</xref>], and the use of gabapentinoids before and a few days after surgery not only significantly decreased perioperative pain [<xref rid="onco12194-bib-0009" ref-type="ref">9</xref>] but also seemed to reduce chronic post&#x02010;surgical pain.</p><p>Based on this rationale, we tested the hypothesis that the preemptive use of pregabalin a few days before and after OXA would have a preventive effect on chronic OXAIPN and its most troublesome symptom: neuropathic pain. However, we found no effects of pregabalin in this scenario. It failed to impact both the acute and chronic pains seen after OXA. Pain&#x02010;related effects, interference, and quality of life were not influenced by the active treatment.</p><p>Previous studies have tried to prevent [<xref rid="onco12194-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12194-bib-0011" ref-type="ref">11</xref>] or treat [<xref rid="onco12194-bib-0012" ref-type="ref">12</xref>] OXA&#x02010;induced neuropathy with limited or no success. While some studies have tested a prophylactic approach to OXA&#x02010;induced neuropathy by administering drugs before chemotherapy was started [<xref rid="onco12194-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12194-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12194-bib-0013" ref-type="ref">13</xref>], [<xref rid="onco12194-bib-0014" ref-type="ref">14</xref>], [<xref rid="onco12194-bib-0015" ref-type="ref">15</xref>], others have focused on patients already with OXAIPN [<xref rid="onco12194-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12194-bib-0016" ref-type="ref">16</xref>], [<xref rid="onco12194-bib-0017" ref-type="ref">17</xref>] and already presenting with neuropathic symptoms [<xref rid="onco12194-bib-0018" ref-type="ref">18</xref>], thus performing a formal treatment trial rather than a preemptive or prophylactic approach. The bulk of evidence is negative for both scenarios [<xref rid="onco12194-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12194-bib-0014" ref-type="ref">14</xref>], [<xref rid="onco12194-bib-0019" ref-type="ref">19</xref>], [<xref rid="onco12194-bib-0020" ref-type="ref">20</xref>], with rare exceptions [<xref rid="onco12194-bib-0017" ref-type="ref">17</xref>], [<xref rid="onco12194-bib-0021" ref-type="ref">21</xref>]. Importantly, the large majority of studies have not used validated pain measurement tools [<xref rid="onco12194-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12194-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12194-bib-0013" ref-type="ref">13</xref>], [<xref rid="onco12194-bib-0014" ref-type="ref">14</xref>], [<xref rid="onco12194-bib-0016" ref-type="ref">16</xref>], [<xref rid="onco12194-bib-0019" ref-type="ref">19</xref>], [<xref rid="onco12194-bib-0022" ref-type="ref">22</xref>], [<xref rid="onco12194-bib-0023" ref-type="ref">23</xref>], while most have used the common terminology criteria (CTC) adverse events grading system as the primary outcome measurement. While this choice is sound and supported by robust evidence [<xref rid="onco12194-bib-0024" ref-type="ref">24</xref>], it must be kept in mind that most patients with OXAIPN have small&#x02010;fiber&#x02010;predominant polyneuropathy [<xref rid="onco12194-bib-0001" ref-type="ref">1</xref>], which has as its main symptom neuropathic pain. However, pain itself (i.e., visual analog scale (VAS), BPI) or neuropathic pain symptoms (i.e., NPSI) have rarely been used as a primary outcome in studies on OXAIPN, and only a few have used validated pain scales or questionnaires at all [<xref rid="onco12194-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12194-bib-0020" ref-type="ref">20</xref>], [<xref rid="onco12194-bib-0021" ref-type="ref">21</xref>], [<xref rid="onco12194-bib-0025" ref-type="ref">25</xref>]. Also, neuropathic symptoms have only rarely been evaluated [<xref rid="onco12194-bib-0017" ref-type="ref">17</xref>], [<xref rid="onco12194-bib-0026" ref-type="ref">26</xref>]. In fact, &#x0201c;pain&#x0201d; is not mentioned in the CTC grading system for &#x0201c;neuropathy&#x0201d;, which is centered on the functional impairment due to paresthesia. It is also noteworthy that no larger trial published so far used formal neuropathic pain criteria or grading system [<xref rid="onco12194-bib-0027" ref-type="ref">27</xref>] among its endpoints, or one of the many published screening tools for neuropathic pain.</p><p>Even though the results of our study are in line with the previous literature, the study has limitations. For instance, the incidence of chronic neuropathic pain was only mild in our sample, maybe due to the inclusion of patients with metastatic disease, who may receive fewer cycles of Oxa. The current management of acute OXA&#x02010;induced dysesthesias by reduction of OXA dosage in subsequent chemotherapy sessions may have also played a role in the reduction of chronic OXAINP in our sample. Also, the placebo group receive significantly more medication than the pregabalin arm. However, the net difference between groups was equivalent to approximately one pill of medication (75 mg). Because the average participant took 5 to 6 pills daily and all participants were pregabalin&#x02010;n&#x000fb;&#x000a3;ve, we believe this may not have played a major role in our results.</p><p>In conclusion, the use of pregabalin failed to decrease acute or chronic OXA&#x02010;related pain despite being safe and relatively well tolerated.</p></sec><sec id="onco12194-sec-1005"><title>Figures and Tables</title><fig fig-type="Figure" xml:lang="en" id="onco12194-fig-0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Effects of study medications on pain intensity. <bold>(A)</bold>: Brief Pain Inventory pain intensity scores (0&#x02013;10). <bold>(B)</bold>: Neuropathic pain symptoms (Douleur Neuropatique&#x02010;4). Statistical significance is considered when confidence intervals from both groups do not intersect.</p><p>*Main outcome.</p><p>Abbreviations: BPI, brief pain inventory; DN&#x02010;4, Douleur Neuropatique&#x02010;4.</p></caption><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12194-fig-0002"><alt-text>image</alt-text></graphic></fig><table-wrap id="onco12194-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline characteristics in both study groups</title></caption><graphic id="nlm-graphic-11" specific-use="sourcefile-name" xlink:href="onco12194-tbl-0002"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12194-note-0001"><p>For all these scores/questionnaires (VAS, HADS, rTNS), higher values indicate more pain/more intense mood symptoms/more signs of neuropathy.</p></fn><fn id="onco12194-note-0002"><p>The values are presented as mean&#x02009;&#x000b1;&#x02009;SD or <italic>n</italic>. Statistical significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05.</p></fn><fn id="onco12194-note-1003"><p>Abbreviations: HADS, hospital anxiety and depression scale; rTNS, total neuropathy score&#x02010;reduced; SD, standard deviation; VAS, visual analog scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12194-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Study outcomes taking into account all measurements over the entire trial period</title></caption><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12194-tbl-0003"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12194-note-1004"><p>The values were presented as predicted means from generalized estimating equations (95% CI). Statistical significance is considered when CI from both groups do not intersect.</p></fn><fn id="onco12194-note-1005"><p>For all these scores/questionnaires (BPI, DN4, HADS, rTNS), higher values indicate more pain/more intense mood symptoms/more signs of neuropathy.</p></fn><fn id="onco12194-note-1006"><label>a</label><p>Main outcome.</p></fn><fn id="onco12194-note-0007"><p>Abbreviations: BPI, brief pain inventory; CI, confidence interval; DN&#x02010;4, Douleur Neuropathique&#x02010;4; HADS, hospital anxiety and depression scale; NPSI, neuropathic pain symptom inventory; rTNS, total neuropathy score&#x02010;reduced.</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12194-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Pain outcomes comparison between interventions considering the dichotomous variables</title></caption><graphic id="nlm-graphic-15" specific-use="sourcefile-name" xlink:href="onco12194-tbl-0004"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12194-note-0008"><p>For all these scores/questionnaires, higher values indicate more severe symptoms.</p></fn><fn id="onco12194-note-0009"><p>Abbreviations: CI, confidence interval; CTC, common toxicity criteria; DN&#x02010;4, Douleur Neuropathique&#x02010;4; VAS, visual analog scale.</p></fn></table-wrap-foot></table-wrap></sec></body><back><ack id="onco12194-sec-0007"><title>Acknowledgments</title><p>The authors thank the patients, who have endured the clinical and neurophysiological assessments during this trial in the hope that a more reliable symptomatic control could be achieved for those affected by OXAIPN and neuropathic pain. This research was partially funded by an investigator&#x02010;initiated research grant from Pfizer (WS55072), the Pain Center Department of Neurology (USP), and Funda&#x000e7;&#x000e3;o de Amparo a Pesquisa do Estado de Sao Paulo.</p></ack><fn-group><fn fn-type="other" id="onco12194-note-2351"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov Identifier</ext-link>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01450163">NCT01450163</ext-link></p><p><bold>Sponsor(s)</bold>: Pfizer, the Pain Center Department of Neurology (USP), and Funda&#x000e7;&#x000e3;o de Amparo a Pesquisa do Estado de Sao Paulo</p><p><bold>Principal Investigators</bold>: Daniel Ciampi de Andrade</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12194-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn></fn-group><sec id="onco12194-sec-0008" sec-type="disclosure"><title>Disclosures</title><p><bold>Didier Bouhassira:</bold> Pfizer, Grunenthal, TEVA (C/A); <bold>Karine S.L. Ferreira:</bold> Johnson &#x00026; Johnson (E); The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12194-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12194-cit-0001">
<string-name><surname>Attal</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Bouhassira</surname>
<given-names>D</given-names></string-name>, 
<string-name><surname>Gautron</surname>
<given-names>M</given-names></string-name> et al. <article-title>Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study</article-title>. <source>Pain</source>
<year>2009</year>;<volume>144</volume>:<fpage>245</fpage>&#x02013;<lpage>252</lpage>.
<pub-id pub-id-type="pmid">19457614</pub-id></mixed-citation></ref><ref id="onco12194-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12194-cit-0002">
<string-name><surname>Ventzel</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Jensen</surname>
<given-names>AB</given-names></string-name>, 
<string-name><surname>Jensen</surname>
<given-names>AR</given-names></string-name> et al. <article-title>Chemotherapy&#x02010;induced pain and neuropathy: A prospective study in patients treated with adjuvant oxaliplatin or docetaxel</article-title>. <source>Pain</source>
<year>2016</year>;<volume>157</volume>:<fpage>560</fpage>&#x02013;<lpage>568</lpage>.
<pub-id pub-id-type="pmid">26529271</pub-id></mixed-citation></ref><ref id="onco12194-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12194-cit-0003">
<string-name><surname>Nikolajsen</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Ilkjaer</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Kr&#x000f8;ner</surname>
<given-names>K</given-names></string-name> et al. <article-title>The influence of preamputation pain on postamputation stump and phantom pain</article-title>. <source>Pain</source>
<year>1997</year>;<volume>72</volume>:<fpage>393</fpage>&#x02013;<lpage>405</lpage>.
<pub-id pub-id-type="pmid">9313280</pub-id></mixed-citation></ref><ref id="onco12194-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12194-cit-0004">
<string-name><surname>Zeilig</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Enosh</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Rubin&#x02010;Asher</surname>
<given-names>D</given-names></string-name> et al. <article-title>The nature and course of sensory changes following spinal cord injury: Predictive properties and implications on the mechanism of central pain</article-title>. <source>Brain</source>
<year>2012</year>;<volume>135</volume>:<fpage>418</fpage>&#x02013;<lpage>430</lpage>.
<pub-id pub-id-type="pmid">22094538</pub-id></mixed-citation></ref><ref id="onco12194-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12194-cit-0005">
<string-name><surname>Hansen</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Obermann</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>U&#x000e7;eyler</surname>
<given-names>N</given-names></string-name> et al. <article-title>[Clinical application of pain&#x02010;related evoked potentials]</article-title>. <source>Schmerz</source>
<year>2012</year>;<volume>26</volume>:<fpage>8</fpage>&#x02013;<lpage>15</lpage>.
<pub-id pub-id-type="pmid">22134376</pub-id></mixed-citation></ref><ref id="onco12194-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12194-cit-0006">
<string-name><surname>Mihara</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Egashira</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Sada</surname>
<given-names>H</given-names></string-name> et al. <article-title>Involvement of spinal NR2B&#x02010;containing NMDA receptors in oxaliplatin&#x02010;induced mechanical allodynia in rats</article-title>. <source>Mol Pain</source>
<year>2011</year>;<volume>7</volume>:<fpage>8</fpage>.
<pub-id pub-id-type="pmid">21247499</pub-id></mixed-citation></ref><ref id="onco12194-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12194-cit-0007">
<string-name><surname>Schmidt</surname>
<given-names>PC</given-names></string-name>, 
<string-name><surname>Ruchelli</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Mackey</surname>
<given-names>SC</given-names></string-name> et al. <article-title>Perioperative gabapentinoids: Choice of agent, dose, timing, and effects on chronic postsurgical pain</article-title>. <source>Anesthesiology</source>
<year>2013</year>;<volume>119</volume>:<fpage>1215</fpage>&#x02013;<lpage>1221</lpage>.
<pub-id pub-id-type="pmid">24051389</pub-id></mixed-citation></ref><ref id="onco12194-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12194-cit-0008">
<string-name><surname>Buvanendran</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Kroin</surname>
<given-names>JS</given-names></string-name>, 
<string-name><surname>Kari</surname>
<given-names>M</given-names></string-name> et al. <article-title>Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system?</article-title>
<source>Reg Anesth Pain Med</source>
<year>2010</year>;<volume>35</volume>:<fpage>535</fpage>&#x02013;<lpage>538</lpage>.
<pub-id pub-id-type="pmid">20975469</pub-id></mixed-citation></ref><ref id="onco12194-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12194-cit-0009">
<string-name><surname>Buvanendran</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Kroin</surname>
<given-names>JS</given-names></string-name>, 
<string-name><surname>Della Valle</surname>
<given-names>CJ</given-names></string-name> et al. <article-title>Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: A prospective, randomized, controlled trial</article-title>. <source>Anesth Analg</source>
<year>2010</year>;<volume>110</volume>:<fpage>199</fpage>&#x02013;<lpage>207</lpage>.
<pub-id pub-id-type="pmid">19910619</pub-id></mixed-citation></ref><ref id="onco12194-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12194-cit-0010">
<string-name><surname>Cascinu</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Catalano</surname>
<given-names>V</given-names></string-name>, 
<string-name><surname>Cordella</surname>
<given-names>L</given-names></string-name> et al. <article-title>Neuroprotective effect of reduced glutathione on oxaliplatin&#x02010;based chemotherapy in advanced colorectal cancer: A randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>J Clin Oncol</source>
<year>2002</year>;<volume>20</volume>:<fpage>3478</fpage>&#x02013;<lpage>3483</lpage>.
<pub-id pub-id-type="pmid">12177109</pub-id></mixed-citation></ref><ref id="onco12194-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12194-cit-0011">
<string-name><surname>Gamelin</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Boisdron&#x02010;Celle</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Delva</surname>
<given-names>R</given-names></string-name> et al. <article-title>Prevention of oxaliplatin&#x02010;related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5&#x02010;Fluorouracil and leucovorin for advanced colorectal cancer</article-title>. <source>Clin Cancer Res</source>
<year>2004</year>;<volume>10</volume>:<fpage>4055</fpage>&#x02013;<lpage>4061</lpage>.
<pub-id pub-id-type="pmid">15217938</pub-id></mixed-citation></ref><ref id="onco12194-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12194-cit-0012">
<string-name><surname>Nagashima</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Ooshiro</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Moriyama</surname>
<given-names>A</given-names></string-name> et al. <article-title>Efficacy and tolerability of controlled&#x02010;release oxycodone for oxaliplatin&#x02010;induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients</article-title>. <source>Support Care Cancer</source>
<year>2014</year>;<volume>22</volume>:<fpage>1579</fpage>&#x02013;<lpage>1584</lpage>.
<pub-id pub-id-type="pmid">24452412</pub-id></mixed-citation></ref><ref id="onco12194-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="onco12194-cit-0013">
<string-name><surname>Argyriou</surname>
<given-names>AA</given-names></string-name>, 
<string-name><surname>Chroni</surname>
<given-names>E</given-names></string-name>, 
<string-name><surname>Polychronopoulos</surname>
<given-names>P</given-names></string-name> et al. <article-title>Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin&#x02010;induced neuropathy</article-title>. <source>Neurology</source>
<year>2006</year>;<volume>67</volume>:<fpage>2253</fpage>&#x02013;<lpage>2255</lpage>.
<pub-id pub-id-type="pmid">17190958</pub-id></mixed-citation></ref><ref id="onco12194-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="onco12194-cit-0014">
<string-name><surname>Kautio</surname>
<given-names>AL</given-names></string-name>, 
<string-name><surname>Haanp&#x000e4;&#x000e4;</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Leminen</surname>
<given-names>A</given-names></string-name> et al. <article-title>Amitriptyline in the prevention of chemotherapy&#x02010;induced neuropathic symptoms</article-title>. <source>Anticancer Res</source>
<year>2009</year>;<volume>29</volume>:<fpage>2601</fpage>&#x02013;<lpage>2606</lpage>.
<pub-id pub-id-type="pmid">19596934</pub-id></mixed-citation></ref><ref id="onco12194-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="onco12194-cit-0015">
<string-name><surname>Grothey</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Nikcevich</surname>
<given-names>DA</given-names></string-name>, 
<string-name><surname>Sloan</surname>
<given-names>JA</given-names></string-name> et al. <article-title>Intravenous calcium and magnesium for oxaliplatin&#x02010;induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7</article-title>. <source>J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>421</fpage>&#x02013;<lpage>427</lpage>.
<pub-id pub-id-type="pmid">21189381</pub-id></mixed-citation></ref><ref id="onco12194-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="onco12194-cit-0016">
<string-name><surname>Penz</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Kornek</surname>
<given-names>GV</given-names></string-name>, 
<string-name><surname>Raderer</surname>
<given-names>M</given-names></string-name> et al. <article-title>Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin&#x02010;related peripheral sensitive neuropathy</article-title>. <source>Ann Oncol</source>
<year>2001</year>;<volume>12</volume>:<fpage>421</fpage>&#x02013;<lpage>422</lpage>.
<pub-id pub-id-type="pmid">11332158</pub-id></mixed-citation></ref><ref id="onco12194-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="onco12194-cit-0017">
<string-name><surname>Durand</surname>
<given-names>JP</given-names></string-name>, 
<string-name><surname>Deplanque</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Montheil</surname>
<given-names>V</given-names></string-name> et al. <article-title>Efficacy of venlafaxine for the prevention and relief of oxaliplatin&#x02010;induced acute neurotoxicity: Results of EFFOX, a randomized, double&#x02010;blind, placebo&#x02010;controlled phase III trial</article-title>. <source>Ann Oncol</source>
<year>2012</year>;<volume>23</volume>:<fpage>200</fpage>&#x02013;<lpage>205</lpage>.
<pub-id pub-id-type="pmid">21427067</pub-id></mixed-citation></ref><ref id="onco12194-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="onco12194-cit-0018">
<string-name><surname>Paatero</surname>
<given-names>P</given-names></string-name>, 
<string-name><surname>Tapper</surname>
<given-names>U.</given-names></string-name>
<article-title>Positive matrix factorization: A non&#x02010;negative factor model with optimal utilization of error estimates of data values</article-title>. <source>Environmetrics</source>
<year>1994</year>;<volume>5</volume>:<fpage>111</fpage>&#x02013;<lpage>126</lpage>.
</mixed-citation></ref><ref id="onco12194-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="onco12194-cit-0019">
<string-name><surname>Loprinzi</surname>
<given-names>CL</given-names></string-name>, 
<string-name><surname>Qin</surname>
<given-names>R</given-names></string-name>, 
<string-name><surname>Dakhil</surname>
<given-names>SR</given-names></string-name> et al. <article-title>Phase III randomized, placebo&#x02010;controlled, double&#x02010;blind study of intravenous calcium and magnesium to prevent oxaliplatin&#x02010;induced sensory neurotoxicity (N08CB/Alliance)</article-title>. <source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>:<fpage>997</fpage>&#x02013;<lpage>1005</lpage>.
<pub-id pub-id-type="pmid">24297951</pub-id></mixed-citation></ref><ref id="onco12194-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="onco12194-cit-0020">
<string-name><surname>Rao</surname>
<given-names>RD</given-names></string-name>, 
<string-name><surname>Michalak</surname>
<given-names>JC</given-names></string-name>, 
<string-name><surname>Sloan</surname>
<given-names>JA</given-names></string-name> et al. <article-title>Efficacy of gabapentin in the management of chemotherapy&#x02010;induced peripheral neuropathy: A phase 3 randomized, double&#x02010;blind, placebo&#x02010;controlled, crossover trial (N00C3)</article-title>. <source>Cancer</source>
<year>2007</year>;<volume>110</volume>:<fpage>2110</fpage>&#x02013;<lpage>2118</lpage>.
<pub-id pub-id-type="pmid">17853395</pub-id></mixed-citation></ref><ref id="onco12194-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="onco12194-cit-0021">
<string-name><surname>Smith</surname>
<given-names>EM</given-names></string-name>, 
<string-name><surname>Pang</surname>
<given-names>H</given-names></string-name>, 
<string-name><surname>Cirrincione</surname>
<given-names>C</given-names></string-name> et al. <article-title>Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy&#x02010;induced painful peripheral neuropathy: A randomized clinical trial</article-title>. <source>JAMA</source>
<year>2013</year>;<volume>309</volume>:<fpage>1359</fpage>&#x02013;<lpage>1367</lpage>.
<pub-id pub-id-type="pmid">23549581</pub-id></mixed-citation></ref><ref id="onco12194-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="onco12194-cit-0022">
<string-name><surname>Kono</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Hata</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Morita</surname>
<given-names>S</given-names></string-name> et al. <article-title>Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double&#x02010;blind, placebo&#x02010;controlled trial of goshajinkigan to prevent oxaliplatin&#x02010;induced neuropathy</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2013</year>;<volume>72</volume>:<fpage>1283</fpage>&#x02013;<lpage>1290</lpage>.
<pub-id pub-id-type="pmid">24121454</pub-id></mixed-citation></ref><ref id="onco12194-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="onco12194-cit-0023">
<string-name><surname>Afonseca</surname>
<given-names>SO</given-names></string-name>, 
<string-name><surname>Cruz</surname>
<given-names>FM</given-names></string-name>, 
<string-name><surname>Cubero</surname>
<given-names>Dde I</given-names></string-name> et al. <article-title>Vitamin E for prevention of oxaliplatin&#x02010;induced peripheral neuropathy: A pilot randomized clinical trial</article-title>. <source>Sao Paulo Med J</source>
<year>2013</year>;<volume>131</volume>:<fpage>35</fpage>&#x02013;<lpage>38</lpage>.
<pub-id pub-id-type="pmid">23538593</pub-id></mixed-citation></ref><ref id="onco12194-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="onco12194-cit-0024">
<string-name><surname>Hershman</surname>
<given-names>DL</given-names></string-name>, 
<string-name><surname>Lacchetti</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Dworkin</surname>
<given-names>RH</given-names></string-name> et al. <article-title>Prevention and management of chemotherapy&#x02010;induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>:<fpage>1941</fpage>&#x02013;<lpage>1967</lpage>.
<pub-id pub-id-type="pmid">24733808</pub-id></mixed-citation></ref><ref id="onco12194-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="onco12194-cit-0025">
<string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, 
<string-name><surname>Gao</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Wang</surname>
<given-names>X</given-names></string-name> et al. <article-title>Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson's disease patients</article-title>. <source>Stereotact Funct Neurosurg</source>
<year>2008</year>;<volume>86</volume>:<fpage>237</fpage>&#x02013;<lpage>244</lpage>.
<pub-id pub-id-type="pmid">18477840</pub-id></mixed-citation></ref><ref id="onco12194-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="onco12194-cit-0026">
<string-name><surname>Kus</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Aktas</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Alpak</surname>
<given-names>G</given-names></string-name> et al. <article-title>Efficacy of venlafaxine for the relief of taxane and oxaliplatin&#x02010;induced acute neurotoxicity: A single&#x02010;center retrospective case&#x02010;control study</article-title>. <source>Support Care Cancer</source>
<year>2016</year>;<volume>24</volume>:<fpage>2085</fpage>&#x02013;<lpage>2091</lpage>.
<pub-id pub-id-type="pmid">26546457</pub-id></mixed-citation></ref><ref id="onco12194-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="onco12194-cit-0027">
<string-name><surname>Treede</surname>
<given-names>RD</given-names></string-name>, 
<string-name><surname>Jensen</surname>
<given-names>TS</given-names></string-name>, 
<string-name><surname>Campbell</surname>
<given-names>JN</given-names></string-name> et al. <article-title>Neuropathic pain: Redefinition and a grading system for clinical and research purposes</article-title>. <source>Neurology</source>
<year>2008</year>;<volume>70</volume>:<fpage>1630</fpage>&#x02013;<lpage>1635</lpage>.
<pub-id pub-id-type="pmid">18003941</pub-id></mixed-citation></ref><ref id="onco12194-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="onco12194-cit-0028">
<string-name><surname>Cleeland</surname>
<given-names>CS</given-names></string-name>, 
<string-name><surname>Ryan</surname>
<given-names>KM</given-names></string-name>. <article-title>Pain assessment: Global use of the Brief Pain Inventory</article-title>. <source>Ann Acad Med Singapore</source>
<year>1994</year>;<volume>23</volume>:<fpage>129</fpage>&#x02013;<lpage>138</lpage>.
<pub-id pub-id-type="pmid">8080219</pub-id></mixed-citation></ref><ref id="onco12194-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="onco12194-cit-0029">
<string-name><surname>Melzack</surname>
<given-names>R.</given-names></string-name>
<article-title>The McGill Pain Questionnaire: Major properties and scoring methods</article-title>. <source>Pain</source>
<year>1975</year>;<volume>1</volume>:<fpage>277</fpage>&#x02013;<lpage>299</lpage>.
<pub-id pub-id-type="pmid">1235985</pub-id></mixed-citation></ref><ref id="onco12194-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="onco12194-cit-0030">
<string-name><surname>Ferreira</surname>
<given-names>KA</given-names></string-name>, 
<string-name>
<surname>de Andrade</surname>
<given-names>DC</given-names></string-name>, 
<string-name><surname>Teixeira</surname>
<given-names>MJ.</given-names></string-name>
<article-title>Development and validation of a Brazilian version of the short&#x02010;form McGill pain questionnaire (SF&#x02010;MPQ). Pain</article-title>
<source>Manag Nurs</source>
<year>2013</year>;<volume>14</volume>:<fpage>210</fpage>&#x02013;<lpage>219</lpage>.
</mixed-citation></ref><ref id="onco12194-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="onco12194-cit-0031">
<string-name><surname>Santos</surname>
<given-names>JG</given-names></string-name>, 
<string-name><surname>Brito</surname>
<given-names>JO</given-names></string-name>, 
<string-name>
<surname>de Andrade</surname>
<given-names>DC</given-names></string-name> et al. <article-title>Translation to Portuguese and validation of the Douleur Neuropathique 4 questionnaire</article-title>. <source>J Pain</source>
<year>2010</year>;<volume>11</volume>:<fpage>484</fpage>&#x02013;<lpage>490</lpage>.
<pub-id pub-id-type="pmid">20015708</pub-id></mixed-citation></ref><ref id="onco12194-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="onco12194-cit-0032">
<string-name><surname>de Andrade</surname>
<given-names>DC</given-names></string-name>, 
<string-name><surname>Ferreira</surname>
<given-names>KA</given-names></string-name>, 
<string-name><surname>Nishimura</surname>
<given-names>CM</given-names></string-name> et al. <article-title>Psychometric validation of the Portuguese version of the Neuropathic Pain Symptoms Inventory</article-title>. <source>Health Qual Life Outcomes</source>. <year>2011</year>;<volume>9</volume>:<fpage>107</fpage>.
<pub-id pub-id-type="pmid">22128801</pub-id></mixed-citation></ref><ref id="onco12194-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="onco12194-cit-0033">
<string-name><surname>Bouhassira</surname>
<given-names>D</given-names></string-name>, 
<string-name><surname>Attal</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Fermanian</surname>
<given-names>J</given-names></string-name> et al. <article-title>Development and validation of the Neuropathic Pain Symptom Inventory</article-title>. <source>Pain</source>
<year>2004</year>;<volume>108</volume>:<fpage>248</fpage>&#x02013;<lpage>257</lpage>.
<pub-id pub-id-type="pmid">15030944</pub-id></mixed-citation></ref><ref id="onco12194-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="onco12194-cit-0034">
<string-name><surname>Cavaletti</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Frigeni</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Lanzani</surname>
<given-names>F</given-names></string-name> et al. <article-title>The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy&#x02010;induced peripheral neurotoxicity: Comparison with the National Cancer Institute&#x02010;Common Toxicity Scale</article-title>. <source>J Peripher Nerv Syst</source>
<year>2007</year>;<volume>12</volume>:<fpage>210</fpage>&#x02013;<lpage>215</lpage>.
<pub-id pub-id-type="pmid">17868248</pub-id></mixed-citation></ref><ref id="onco12194-bib-0035"><label>35</label><mixed-citation publication-type="miscellaneous" id="onco12194-cit-0035"><collab collab-type="authors">National Cancer Institute</collab>
: Common Terminology Criteria for Adverse Events, 2003. Available at <ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov">http://ctep.cancer.gov</ext-link>. Accessed June 9, 2017.
</mixed-citation></ref><ref id="onco12194-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="onco12194-cit-0036">
<string-name><surname>Cavaletti</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Bogliun</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Marzorati</surname>
<given-names>L</given-names></string-name> et al. <article-title>Grading of chemotherapy&#x02010;induced peripheral neurotoxicity using the Total Neuropathy Scale</article-title>. <source>Neurology</source>
<year>2003</year>;<volume>61</volume>:<fpage>1297</fpage>&#x02013;<lpage>1300</lpage>.
<pub-id pub-id-type="pmid">14610145</pub-id></mixed-citation></ref><ref id="onco12194-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="onco12194-cit-0037">
<string-name><surname>Zigmond</surname>
<given-names>AS</given-names></string-name>, 
<string-name><surname>Snaith</surname>
<given-names>RP</given-names></string-name>. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;<volume>67</volume>:<fpage>361</fpage>&#x02013;<lpage>370</lpage>.
</mixed-citation></ref><ref id="onco12194-bib-0038"><label>38</label><mixed-citation publication-type="book" id="onco12194-cit-0038">
<string-name><surname>Kuhn</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Johnson</surname>
<given-names>K.</given-names></string-name>
<source>Applied predictive modeling</source>. <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2013</year>.
</mixed-citation></ref><ref id="onco12194-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="onco12194-cit-0039">
<string-name><surname>Reshef</surname>
<given-names>DN</given-names></string-name>, 
<string-name><surname>Reshef</surname>
<given-names>YA</given-names></string-name>, 
<string-name><surname>Finucane</surname>
<given-names>HK</given-names></string-name> et al. <article-title>Detecting novel associations in large data sets</article-title>. <source>Science</source>
<year>2011</year>;<volume>334</volume>:<fpage>1518</fpage>&#x02013;<lpage>1524</lpage>.
<pub-id pub-id-type="pmid">22174245</pub-id></mixed-citation></ref><ref id="onco12194-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="onco12194-cit-0040">
<string-name><surname>Prantner</surname>
<given-names>B</given-names></string-name>, <article-title>Visualization of imputed values using the R&#x02010;package VIM</article-title>, <year>2011</year> Available at <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/VIMGUI/vignettes/VIM-Imputation.pdf">https://cran.r&#x02010;project.org/web/packages/VIMGUI/vignettes/VIM&#x02010;Imputation.pdf</ext-link>. Accessed June 9, 2017.
</mixed-citation></ref></ref-list></back></article>